Can a Lab-Made protein restore immune defenses in glioma patients?

NCT ID NCT03687957

Ongoing Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a drug called rhIL-7-hyFc can safely increase lymphocyte counts in people with high-grade glioma who have low immune cells after standard radiation and chemotherapy. About 42 participants will receive either the drug or a placebo by injection. The study first checks safety and dosing, then measures changes in immune cell levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rhIL-7-hyFc (a lab-made protein that may help increase immune cell counts)
What this could lead to: If it works, this could point toward a way to restore immune function in brain cancer patients, potentially helping them fight infections and better tolerate treatment.
What could go wrong: This is a very early, small trial (42 people) testing safety and immune effects, not whether it improves survival. The drug may cause side effects or fail to raise lymphocyte levels meaningfully.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma glioma susceptibility 1 malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.